louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02943928: Placement of the Double-Lumen Tube Without Fiberoptic Bronchoscope Assistance
Official title: Placement of the Double-Lumen Tube Without Fiberoptic Bronchoscope Assistance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Therapeutic Procedural Complication
Lead sponsor: The First Hospital of Qinhuangdao
Sponsor class: OTHER_GOV
First posted: 2016-10-25
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: laryngoscope combined with chest CT in double lumen endotracheal tube accurate positioning

Detailed description: Comparing the traditional method of double lumen endotracheal tube intubation and laryngoscope combined with chest CT guide the precise localization of double lumen endotracheal tube

Eligibility criteria: Inclusion Criteria:

* BMI less than 35 kg/m2
* ASA classifications of I-III, modified Mallampati classification 1 or 2 general anesthesia were included-

Exclusion Criteria:

* Exclusion criteria included age younger than 18 yr
* ASA class IV or V
* Abnormalities of the heart, brain, liver, lung, kidney and coagulation functions-

Primary outcomes:
measure: Intubation Time
timeFrame: Ten minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Qinhuangdao
country: China
facility: 中国
state: Hebei
Study officials:
affiliation: The First Hospital of Qinhuangdao
name: Ximing Qi
role: STUDY_DIRECTOR
References:
Clinical trial NCT04905628: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
Official title: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetes Mellitus
Lead sponsor: DexCom, Inc.
Sponsor class: INDUSTRY
First posted: 2021-05-27
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Age ≥ 18 years
2. Confirmed pregnancy
3. Diagnosis of Gestational Diabetes (GDM), Type 1 Diabetes Mellitus (T1DM), or Type 2 Diabetes Mellitus (T2DM)

Brief summary: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Confirmed pregnancy
* Diagnosis of Gestational Diabetes (GDM), Type 1 Diabetes Mellitus (T1DM), or Type 2 Diabetes Mellitus (T2DM)
* Willing to wear up to the required number of Systems for the total duration of study wear
* Able to follow study procedures;
* Able to speak, read, and write in English or Spanish.

Exclusion Criteria:

* Extensive skin changes/diseases that preclude wearing the required number of Systems at the proposed wear sites
* Known allergy to medical-grade adhesives
* Hematocrit outside specification
* Prescribed drugs for treatment of pre-term labor or experiencing high-risk pregnancy complications during current pregnancy
* Currently receiving dialysis treatment or planning to receive dialysis during the sensor wear period
* Currently using Hydroxyurea for treatment
* Require a Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, or diathermy during the sensor wear period

Primary outcomes:
measure: Dexcom Continuous Glucose Monitoring (CGM) System Performance
timeFrame: 10 Days
Secondary outcomes:
measure: System Related Adverse Device Effects
timeFrame: 10 Days
Other outcomes:
Locations:
city: Santa Barbara
country: United States
facility: Sansum Diabetes Research Institute
state: California
city: Aurora
country: United States
facility: Barbara Davis Center for Childhood Diabetes
state: Colorado
city: Boston
country: United States
facility: Joslin Diabetes Center
state: Massachusetts
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai
state: New York
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: Icahn School of Medicine at Mount Sinai
name: Carol Levy, MD, CDCES
role: PRINCIPAL_INVESTIGATOR
affiliation: Barbara Davis Center
name: Sarit Polsky,, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Joslin Diabetes Center
name: Florence Brown, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Sansum Diabetes Research Institute
name: Kristin Castorino, DO
role: PRINCIPAL_INVESTIGATOR
affiliation: Oregon Health and Science University
name: Amy Valent, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04774328: Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair
Official title: A Three-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics, and Preliminary Efficacy Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Postsurgical Pain
Lead sponsor: Concentric Analgesics
Sponsor class: INDUSTRY
First posted: 2021-03-01
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Three-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics, and Preliminary Efficacy Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair


Eligibility criteria: Inclusion Criteria:

* Scheduled elective, primary, open laparotomy with VHR, with retromuscular, preperitoneal mesh placement, with midline fascial reconstruction
* ASA physical class 1, 2, or 3
* BMI \</= 40 kg/m2
* Aged 18-80 years old

Exclusion Criteria:

* Concurrent condition requiring analgesic treatment during study period
* Opioid tolerant
* Known allergy to capsaicin or other study medication
* Use of prohibited medications

Primary outcomes:
measure: Pain at Rest - Part B
timeFrame: Up to 96 hours
Secondary outcomes:
measure: Evoked NRS - Part B
timeFrame: Up to 96 hours
measure: Opioid Consumption - Part B
timeFrame: Up to Day 8
Other outcomes:
Locations:
city: Houston
country: United States
facility: First Surgical Hospital
state: Texas
Study officials:
affiliation: First Surgical Hospital
name: Daneshvari Solanki, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00080028: Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
Official title: Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Head and Neck Cancer
Oropharynx Cancer
Larynx Cancer
Hypopharynx Cancer
Keywords: Head and Neck Cancer
SCCHN
Oropharynx Cancer
Hypopharynx Cancer
Larynx Cancer
Soft palate Cancer
Tonsil Cancer
Base of tongue Cancer
Supraglottic Cancer
Glottic Cancer
Pyriform Sinus Cancer
Pharyngeal wall Cancer
Throat cancer
Lead sponsor: Pharmacyclics LLC.
Sponsor class: INDUSTRY
First posted: 2004-03-23
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Each patient must sign a study-specific informed consent form
* Newly diagnosed, locally advanced, non-metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) arising from a primary site in the oropharynx, hypopharynx, or larynx confirmed by evaluation of fine needle aspiration or biopsy samples and MRI
* Eligible for curative intent treatment with hyperfractionated radiation and concurrent 5-FU and cisplatin
* Karnofsky Performance Status score of at least 60%
* Primary tumor at least 4 cm in diameter

Exclusion Criteria:

Laboratory Values of:

* Serum creatinine \> 1.8 mg/dL; unless 24-hour urine creatinine clearance is ≥ 70 mL/min
* Serum total bilirubin \> 1.5 times the upper limit of normal
* ALT (formerly SGPT) \> 1.5 times the upper limit of normal
* Alkaline phosphatase \> 1.5 times the upper limit of normal
* Absolute neutrophil count (ANC) \< 1500/L
* Platelet count \< 100,000/L
* 3+ or greater proteinuria on urinalysis

and

* Squamous Cell Carcinoma of the Head and Neck arising from a primary site in the oral cavity or nasopharynx
* Distant metastases
* Prior history of cancer at any site treated with radiotherapy and/or chemotherapy
* History of SCCHN diagnosed within 5 years of current diagnosis

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: San Antonio
country: United States
facility: University of Texas, San Antonio Health Science Center
state: Texas
Study officials:
References:
Clinical trial NCT02157428: Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane
Official title: Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adverse Effect of Other General Anesthetics
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2014-06-06
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Background and objectives: The inhalational anesthetic isoflurane is widely used in general anesthetics. Its mechanism of action involves interaction with the receptor of gamma-amino butyric acid (GABA), which is also the binding site for benzodiazepines. Flumazenil, benzodiazepine antagonist, reverses the effects of these drugs in GABA receptors and could therefore also reverse the effect of isoflurane. In anesthesia practice, extubation and early anesthetic recovery reduce morbidity and incidence of complications. The objective of this trial is to determine whether the use of flumazenil may contribute to faster recovery from anesthesia. Methods: 40 patients scheduled to undergo general anesthesia with isoflurane were enrolled in this prospective, double-blind, randomized trial. Patients were randomized to receive, at the end of anesthesia, flumazenil or placebo as allocated into two groups. The anesthetic technique was standardized. The groups were compared concerning values of Cerebral State Index (CSI), heart rate, blood pressure and oxygen saturation from the application of flumazenil or placebo until 30 minutes after injection. Data regarding time to extubation, time to reach ten points in the Aldrete-Kroulic score (AK = 10) and Vigilance score (VS = 10) was also collected. ANOVA test was applied to analyze the results, considering p \<0.05.


Eligibility criteria: Inclusion Criteria:

* patients scheduled to surgeries with general anesthesia,
* healthy or with minor diseases completely controlled by regular use of medications (ASA I or II according to the classification of physical state by the American Society of Anesthesiologists).

Exclusion Criteria:

* patients with past of chronic use of benzodiazepines and/or illicit drugs,
* seizures or panic disorder.

Primary outcomes:
measure: Time of recovery from a general anesthesia isoflurane based
timeFrame: up to 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Hospital Universitário USP
Study officials:
References:
Clinical trial NCT00561028: Chlamydia and Mycoplasma in Coronary Artery Disease
Official title: Prevalence of Chlamydia Pneumoniae and Mycoplasma Pneumoniae in Different Forms of Obstructive Coronary Artery Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atherosclerosis
Coronary Artery Disease
Chlamydia Infections
Mycoplasma Infections
Keywords: Atherosclerosis
Coronary artery disease
Chlamydia pneumoniae
Mycoplasma pneumoniae
Lead sponsor: Hospital de Base
Sponsor class: OTHER
Collaborators: name: University of Sao Paulo
First posted: 2007-11-20
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Group 1 and 2 - selected after admission in coronary care unit. Group 3 - selected from out-patient cardiology clinic. Group 4 - selected from the blood donation unit.

Brief summary: To test the association between anti-Chlamydia serum titers and anti-Mycoplasma antibodies with Acute Coronary Syndromes.

Detailed description: One hundred and twenty-six patients were divided into 4 groups: Acute Coronary Syndrome with ST-elevation, Non-ST-elevation, stable coronary artery disease, and individuals without coronary disease. Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured at baseline and after 6 months.

Eligibility criteria: Inclusion Criteria:

* Age \>18 yrs
* Males and females
* Agreed to sign the informed consent

Exclusion Criteria:

* Refusal to sign the informed consent
* Follow-up not possible
* For the "acute" groups, time between the pain beginning and randomization \>24 hours
* Active infections
* Use of antimicrobial agents within the last 30 days
* End-stage diseases with life expectancy \<6 months

Primary outcomes:
measure: Test the hypothesis that patients with acute coronary syndromes have higher levels of Chlamydia pneumonia and Mycoplasma pneumonia antibodies in comparison with patients with stable coronary artery disease or controls.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Sao Paulo
name: Jose C Nicolau, MD, pHD
role: STUDY_DIRECTOR
References:
citation: Maia IL, Nicolau JC, Machado MN, Maia LN, Takakura IT, Rocha PR, Cordeiro JA, Ramires JA. Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae in different forms of coronary disease. Arq Bras Cardiol. 2009 Jun;92(6):405-11, 422-8, 439-45. doi: 10.1590/s0066-782x2009000600005. English, Multiple languages.
Clinical trial NCT03720028: Angelman & Rett Syndrome: Interaction and Communication
Official title: Parent-child Interaction and Communication in Families Who Have a Child With Rett Syndrome or Angelman Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Behavior, Child
Parent-Child Relations
Communication
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: KU Leuven
First posted: 2018-10-25
Enrollment: 20
Sex: ALL
Minimum age (years): 1
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children with complex communication needs.

Brief summary: We aim to describe the communicative and sensory profile of children with Angelman syndrome or Rett syndrome and their use of augmentative and alternative communication. In addition, parents are surveyed regarding parent-child interaction and access to communication support.


Eligibility criteria: Inclusion Criteria:

* Angelman or Rett syndrome

Exclusion Criteria:

* none

Primary outcomes:
measure: Communication profile
timeFrame: 1 day One-time measurement
measure: Parent interaction
timeFrame: 1 day One-time measurement
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Katholieke Universiteit Leuven
state: Vlaams-Brabant
Study officials:
References:
Clinical trial NCT02005328: Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia
Official title: Study of the Effect and Safety of Three New Oral Sprays and a Reference Marketed Oral Spray in the Relief of Drug-induced Xerostomia Associated With Hyposialia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Drug-induced Xerostomia
Keywords: Xerostomia
hyposialia
hyposalivation
saliva substitute
Salivary Gland
Mouth Diseases
Dry mouth
Lead sponsor: Pierre Fabre Medicament
Sponsor class: INDUSTRY
First posted: 2013-12-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate the clinical efficacy, the safety and acceptability of three new oral sprays with a reference oral spray in the relief of drug-induced xerostomia associated with hyposialia, i.e. dryness of the mouth induced by a decrease of salivation (hyposialia) induced by chronic drug intake.


Eligibility criteria: Inclusion Criteria:

* Male and female subjects,
* Adult subjects (≥18 years) taking drug(s) causing salivary hypofunction / xerostomia, for at least 1 week prior to study initiation and expected to continue without change during study
* Subjects with a complaint of dry mouth as assessed by a response of 40mm or greater on item "Rate the dryness of your mouth" of the Dry Mouth Visual Analogue Scale (VAS) questions. (The VAS limits will be 0 representing normal \[i.e. no dry mouth symptoms\] and 100 representing "the worst imaginable" dry mouth symptoms). This score should also be met before the 1st product application, on P1 D1.
* Documented hyposalivation with test of resting saliva weight absorbed ≤ 0.5g/5 min at baseline

Exclusion Criteria:

* Presence of disorders (bucco-dental disease, history of major medical/psychiatric illness or surgery, ... ) which, in the judgement of the investigator, may interfere with study implementation and/or study parameter assessment(s).
* Sjögren syndrome and related autoimmune diseases,
* Other medical causes of xerostomia (oral candidiasis).
* History of head and neck irradiation and cancer chemotherapy
* History of hypersensitivity to any of the components of the investigational products,
* History or current excessive use of alcohol,
* History of drug addiction,
* Presence of treatments for their dry mouth within 7 days prior to inclusion into the study

Primary outcomes:
measure: Observed area under the curve of dry mouth evaluations
timeFrame: 11 points : from baseline (before application) and up to 4 hours after the first product application
Secondary outcomes:
Other outcomes:
Locations:
city: Erfurt
country: Germany
Study officials:
References:
Clinical trial NCT04142528: Patient-Centered PD Ambulatory Monitoring System
Official title: ParkinPal: Patient-Centered PD Ambulatory Monitoring System
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Parkinson Disease
Lead sponsor: Great Lakes NeuroTechnologies Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institute of Nursing Research (NINR)
First posted: 2019-10-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population is people with Parkinson's Disease who are patients of David E. Riley, MD. Therefore most participants will reside in the northeast Ohio area.

Brief summary: This a usability study of a wearable sensor platform that utilizes a smartwatch to periodically record motion data. That data is processed in a connected smartphone and translated into symptom scores for dyskinesia, slowness, and tremor. The research subjects will use the wearable system over the course of five weeks, during which a change in therapy regimen is prescribed by the physician. Research analysis will be focused on patient and clinician experiences with the app and its reports.


Eligibility criteria: Inclusion Criteria:

* Existing Patient of Collaborating Physician (David E. Riley, MD)
* Diagnosed With Parkinson's Disease
* Hoehn \& Yahr Scale I-III
* Ambulatory and capable of using the ParkinPal system
* Able to understand and follow instructions regarding using the device

Exclusion Criteria:

* Any subject that does not meet the subject selection criteria will be excluded from this study. Children will be excluded from this study due to the fact that they are unlikely to have PD. Subjects that are not capable of functioning independently or are so symptomatic as to compromise their safety will also be excluded.

Primary outcomes:
measure: Useability
timeFrame: 6 weeks
Secondary outcomes:
measure: Symptom scores
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Warrensville Heights
country: United States
facility: David E. Riley, MD
state: Ohio
Study officials:
affiliation: Great Lakes NeuroTechnologies
name: Dustin Heldman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00145028: Determination of Carboplatin's Optimal Plasmatic Exposure
Official title: Determination of Carboplatin's Optimal Plasmatic Exposure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neoplasms
Keywords: Neoplasms
Carboplatin
optimal exposure
AUC
Lead sponsor: Institut Claudius Regaud
Sponsor class: OTHER
First posted: 2005-09-05
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To determine Carboplatin's optimal exposures(optimal AUCs)and parameters they depend on.


Eligibility criteria: Inclusion Criteria:

* Carcinoma histologically proved and which must be treated by Carboplatin, excepted weekly administered Carboplatin treatments
* Age \> 18 years
* Neutrophils \> 1500/mm3, blood-platelets \> 100000/mm3
* Patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for Investigators centers achieving pharmacokinetic examination)
* Well-informed written consent, signed by the patient

Exclusion Criteria:

* Carboplatin treatment's contra-indication
* Patient with clinically detectable cerebral metastasis
* Pregnant or nursing women
* Patient under guardianship or trusteeship
* Patient whose venous status don't permit a peripheral intravenous administration route's placing (for Investigators centers achieving pharmacokinetic examination)

Primary outcomes:
measure: To determine Carboplatin's optimal exposures (optimal AUCs) and parameters they depend on.
Secondary outcomes:
measure: To assign a standardization method for Carboplatin doses's calculation in chemotherapy's protocol including this drug.
Other outcomes:
Locations:
city: Angers
country: France
facility: Centre Paul Papin
city: Bordeaux
country: France
facility: Institut Bergonié
city: Evreux
country: France
facility: Clinique Pasteur
city: Grenoble
country: France
facility: CHU A. Michallon
city: Lille
country: France
facility: Centre Oscar Lambert
city: Marseille
country: France
facility: CHU de la Timone
city: Montpellier
country: France
facility: Centre Val d'Aurelle
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Nîmes
country: France
facility: CHU de Nîmes
city: Paris
country: France
facility: Hopital Européen Georges Pompidou
city: Rouen
country: France
facility: Clinique Mathilde
city: Saint Herblain (Nantes)
country: France
facility: Centre René Gauducheau
city: Toulouse
country: France
facility: CHU de Toulouse Rangueil
city: Toulouse
country: France
facility: Institut Claudius Regaud
city: Tours
country: France
facility: CHRU Bretonneau
Study officials:
affiliation: Institut Claudius Regaud
name: Laurence GLADIEFF, Doctor
role: PRINCIPAL_INVESTIGATOR
References: